^
Association details:
| Biomarker: | HER-2 negative + PD-L1 expression |
|---|---|
| Cancer: | Esophageal Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastrooesophageal junction cancer
Published date:
09/17/2021
Excerpt:
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy is recommended, within its marketing authorisation, as an option for untreated locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a combined positive score (CPS) of 10 or more.
Secondary therapy:
Chemotherapy
Source:
Excerpt:
Esophageal and Esophagogastric Junction Cancers: HER2 overexpression negative…Fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, and pembrolizumab (PDL1 CPS ≥ 10)…Fluoropyrimidine (fluorouracil or capecitabine), cisplatin, and pembrolizumab (PDL1 CPS ≥ 10) (category 1)…
Secondary therapy:
cisplatin + 5-fluorouracil; cisplatin + capecitabine; 5-fluorouracil + oxaliplatin; capecitabine + oxaliplatin
Title:
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer
Excerpt:
Merck...announced the European Commission (EC) has approved two new indications for KEYTRUDA, Merck’s anti-PD-1 therapy, in gastrointestinal cancers...KEYTRUDA in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in adults whose tumors express PD-L1 with a Combined Positive Score (CPS) ≥1.
